A targeted examination of peripheral blood mononuclear cells has revealed specific molecular alterations distinguishing patients with multiple sclerosis from healthy individuals. In a preliminary exploratory study published in Molecular Biomedicine, investigators identified distinct elevations of catechol-o-methyltransferase in cytotoxic T lymphocytes alongside increased survivin expression in circulating B cells. The findings provide new clues into the cell-type specific mechanisms underlying multiple sclerosis pathogenesis and illustrate how restricted dimensional cytometry can capture subtle molecular signatures.
Multiple sclerosis represents an immune-mediated disorder characterized by complex pathophysiological processes involving multiple immune cell subsets and biological signaling molecules. While therapeutic advances such as B cell depletion have demonstrated notable clinical efficacy in treating patients, the cellular mechanisms and molecular drivers responsible for disease activity continue to pose substantial biological questions. Blood mononuclear cells continually circulate throughout the body, acting as a unified surveillance system capable of detecting homeostatic disturbances through specialized surface receptors. By evaluating changes in molecular expression within individual mononuclear cell types, researchers sought to determine whether alterations in readily accessible peripheral blood could reflect pathological activity regardless of the anatomical location of disease lesions.
To investigate these molecular differences, the research team analyzed blood samples obtained from twenty-one patients with stable multiple sclerosis and twenty-one age- and sex-matched healthy control volunteers. The cohort of diagnosed patients included individuals stratified across major diagnostic subtypes, comprising eleven patients diagnosed with secondary progressive multiple sclerosis and nine individuals diagnosed with relapsing/remitting multiple sclerosis. The study protocol explicitly excluded patients undergoing acute clinical relapses, concentrating analytical attention entirely on stable disease periods. A subset of patients was also characterized based on existing pharmaceutical therapies, which included interferon beta-1a, glatiramer acetate, or no active pharmaceutical intervention at the time of cell collection.
The methodological framework relied on restricted dimensional cytometry with enhanced sensitivity to conduct quantitative analyses of specific proteins within defined immune cell populations. Investigators directed their measurements toward four distinct peripheral blood mononuclear cell subsets: CD4+ helper T cells, CD8+ cytotoxic T cells, B cells, and monocytes. Candidate analytes were selected based on prior scientific literature implicating them in multiple sclerosis disease pathogenesis. The experimental panel evaluated seventeen molecular targets, including phospho-Akt, catechol-o-methyltransferase, aryl hydrocarbon receptor, RelA, calmodulin, vitamin D receptor, Bax, BclxL, tumor necrosis factor receptor associated factor 6, survivin, interferon regulatory factor 3, brain-derived neurotrophic factor, tryptophanyl-tRNA synthetase, Bcl2L12, autophagy-related protein 7, interferon regulatory factor 4, and translocator protein.
Across the majority of the seventeen molecular targets evaluated, cell-type specific expression levels remained indistinguishable between patients with multiple sclerosis and healthy controls. However, two prominent molecular deviations emerged from the quantitative screening. Investigators detected a notable increase in catechol-o-methyltransferase expression within CD8+ T cells from multiple sclerosis patients compared to healthy controls. Concurrently, peripheral B cells collected from multiple sclerosis patients exhibited a pronounced increase in survivin expression. Further evaluation of flow cytometric histograms clarified the biophysical nature of these expression patterns: the increased catechol-o-methyltransferase signal in CD8+ T cells arose from a uniform shift in a sharp expression peak, whereas the divergence in B cell survivin expression was driven by an expanded subpopulation of cells occupying a distinct high-expression peak.
The biological roles of these two molecules offer substantive context for their potential involvement in multiple sclerosis pathophysiology. Survivin functions as an anti-apoptotic protein that inhibits programmed cell death and supports cellular survival. The authors noted that latent Epstein-Barr virus infection has been shown to enhance survivin expression, a relevant association given that the virus represents an established factor linked to the development of multiple sclerosis. The presence of a small high-survivin B cell subpopulation among healthy controls suggests that latent viral infection might modulate this baseline cellular pool. Meanwhile, elevated catechol-o-methyltransferase in CD8+ T cells aligns with prior experimental evidence where pharmacological inhibition of this enzyme suppressed experimental autoimmune encephalomyelitis, an established laboratory model of neuroinflammation.
To determine whether the measured molecular elevations corresponded to objective indicators of central nervous system pathology, the researchers conducted Poisson regression modeling using clinical magnetic resonance imaging data. The regression incorporated both the proportion of high-survivin B cells and CD8+ T cell catechol-o-methyltransferase expression as independent variables to explain the count of gadolinium-enhancing brain lesions across twenty evaluated patients. The two variables exhibited no multicollinearity and together accounted for roughly half of the observed variance in gadolinium-enhancing lesion numbers, yielding a coefficient of determination of 0.52. Because gadolinium enhancement serves as an established radiological marker of active inflammation and disease activity, this statistical correlation supports the concept that these specific immune cell perturbations relate directly to ongoing pathological mechanisms.
The investigators also evaluated the diagnostic classification potential of these cellular markers, focusing on the proportion of B cells within the high-survivin expression gate. Using logistic regression, this single metric distinguished multiple sclerosis patients from healthy controls with an overall model p-value of 0.02 and an analyte p-value of 0.05, delivering a classification accuracy of 68 percent and a specificity of 70 percent. Incorporating CD8+ T cell catechol-o-methyltransferase or other candidate molecules did not meaningfully enhance the discriminatory accuracy of the logistic model. When tested specifically to separate relapsing/remitting multiple sclerosis patients from healthy volunteers, the high-survivin B cell proportion achieved 72 percent accuracy, with a model p-value of 0.02, a parameter p-value of 0.03, and an area under the receiver operating characteristic curve of 0.77.
In contrast to the clear distinction seen between patients and healthy volunteers, differentiating disease subtypes proved more statistically challenging. When evaluating patients stratified by clinical diagnosis, logistic regression using the high-survivin B cell parameter differentiated relapsing/remitting multiple sclerosis from secondary progressive multiple sclerosis with an overall model p-value of 0.03, an accuracy of 70 percent, and an area under the curve of 0.71; however, the parameter p-value reached only 0.09. Analyses stratifying patients by pharmaceutical treatment regimens (Avonex, Copaxone, or untreated) revealed no significant differences in B cell survivin or CD8+ T cell catechol-o-methyltransferase levels, indicating that the observed differences were primarily reflective of disease status rather than specific immunomodulatory therapies.
While these initial cytometry findings point to promising cellular markers, the study authors emphasize several critical methodological boundaries and interpretative limitations. The investigation was exploratory in nature and conducted on a relatively small cohort of forty-two total participants, restricted strictly to stable disease states while omitting actively relapsing patients. The authors concluded that validating these molecular differences will require expanded clinical investigations with larger participant cohorts and independent validation groups. Developing clinically actionable, objective diagnostic assays based on peripheral blood mononuclear cells will likely require identifying and combining additional cell-type specific molecular markers alongside B cell survivin and CD8+ T cell catechol-o-methyltransferase.
Subject of Research: Cell-type specific molecular expression in blood mononuclear cells of multiple sclerosis patients
Article Title: Blood mononuclear cell-type specific molecular expression levels distinguishing patients with multiple sclerosis
Article References: Kaplan, D., Kaye, N. M., Christian, E. L., Lazarus, H. M., Planchon, S. M., & Cohen, J. A. (2026). Blood mononuclear cell-type specific molecular expression levels distinguishing patients with multiple sclerosis. Molecular Biomedicine, 7(1), Article 251. https://doi.org/10.1186/s43556-026-00543-z
Image Credits: AI Generated
DOI: 10.1186/s43556-026-00543-z
Keywords: multiple sclerosis, peripheral blood mononuclear cells, B cells, CD8+ T cells, survivin, catechol-o-methyltransferase, flow cytometry, neuroimmunology, gadolinium-enhancing lesions, magnetic resonance imaging, biomarkers, Epstein-Barr virus, secondary progressive MS, relapsing-remitting MS, restricted dimensional cytometry, immune profiling
News Source: Drew Townsend. (November 20, 2026). Blood Cell Protein Patterns Distinguish Patients With Multiple Sclerosis in Exploratory Study. Scienmag.



